Calliditas Therapeutics AB

CALTX

SE0010441584

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:52 2024-04-26 am EDT			5-day change	1st Jan Change
103.7 ^SEK	-0.38%		+3.18%	-18.41%

Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT
Apr. 24	Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	MT

Calliditas Therapeutics to Attend Investor Conferences in March

March 04, 2024 at 09:31 am EST

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ('Calliditas'), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.

Carnegie Healthcare Seminar, Wednesday, March 6, 2024. Fireside chat will be held at 10:20 - 10:50 am CET and one-on-one meetings will be available.

Jefferies Biotech on the Bay Summit, Wednesday, March 13, 2024 in Miami, FL, one-on-one meetings will be available.

Leerink Partners Global Biopharma Conference on March 12, 2024 in Miami, FL.

Contact:

Asa Hillsten

Tel: +46 76 403 35 43

Email: asa.hillsten@calliditas.com

Latest news about Calliditas Therapeutics AB

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	Apr. 24	MT
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results	Apr. 24	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires	Apr. 08	CI
Calliditas Therapeutics Gets US Patent Allowance for Cancer Treatment Inhibitor	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®	Mar. 11	CI
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	Mar. 06	MT
Calliditas Therapeutics Gets US FDA Orphan Drug Exclusivity for Kidney Disease Drug	Mar. 06	MT

Chart Calliditas Therapeutics AB

Duration

Period

More charts

Company Profile

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Sector

Pharmaceuticals

Calendar

2024-04-28 - LSX World Congress

More about the company

Income Statement Evolution

More financial data

Ratings for Calliditas Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

103.7 SEK

Average target price

208 SEK

Spread / Average Target

+100.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CALLIDITAS THERAPEUTICS AB	-18.41%	508M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals

Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Pharmaceuticals

Calliditas Therapeutics to Attend Investor Conferences in March

EPS Revisions